Related Experiment Video

Updated: Oct 23, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Abnormal indomethacin-sensitive suppression in peripheral blood mononuclear cells of cancer patients restricts

D P Braun, J E Harris

    Journal of Biological Response Modifiers
    |October 1, 1984
    PubMed

    The capacity of the immunomodulators interleukin-2 (IL-2) and indomethacin to augment phytohemagglutinin (PHA)-induced lymphoproliferation in the peripheral blood mononuclear cells (PBMC) of cancer patients was evaluated. Ficoll-Hypaque-isolated PBMC from 20 patients with disseminated non-lymphoreticular solid tumors were stimulated with PHA in the presence of IL-2, indomethacin, or IL-2 plus indomethacin. Augmentation of PHA responsiveness by each immunomodulator was additive. There was a significant negative correlation between PHA reactivity and immunomodulation by indomethacin. There was no correlation between PHA reactivity and immunomodulation by IL-2. A significant negative correlation was also found between indomethacin-induced augmentation and IL-2-induced augmentation in patients with significantly impaired reactivity to PHA. Still, the combined effects of IL-2 and indomethacin could not prevent the suppressive effects of prostaglandin E2 added to PHA-stimulated cultures containing both immunomodulators. These results suggest that the presence of abnormal indomethacin-sensitive immunoregulation in PBMC from cancer patients limits lymphocyte responsiveness to IL-2 and suggests that these two immunomodulators might be combined in certain cancer patient therapies.

    More Related Videos

    Expansion of Human Peripheral Blood γδ T Cells using Zoledronate13:08

    Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

    Published on: September 9, 2011

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

    Published on: July 20, 2019

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Inflammatory Bowel Disease III: Crohn's Disease01:25

    Inflammatory Bowel Disease III: Crohn's Disease

    Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...